Bladder cancer screening with urine-based tumour markers - Occupational medical experience;Das Screening von Harnblasenkarzinomen mittels urinbasierter Tumormarker - Erfahrungen aus der Arbeitsmedizin

Aktuelle Urologie

Volumn 42, Issue 2, 2011, Pages 128-134

  Nasterlack, M ^a   Feil, G ^b   Leng, G ^c   Pesch, B ^d   Huber, S ^b   Sievert, K D ^b   Johnen, G ^d   Taeger, D ^d   Mayer, T ^a   Kluckert, M ^e   Bruning T ^d   Stenzl, A ^b  

^a BASF SE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Bayer Industry Services GmbH and Co OHG   (Germany)

^d INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^e Berufsgenossenschaft Rohstoffe und Chemische Industrie   (Germany)

Author keywords

bladder cancer; cytology; hematuria; screening; tumour markers

Indexed keywords

EID: 79952843178     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0031-1271424     Document Type: Article

References (43)

1. Robert Koch Institut (RKI). Krebs in Deutschland 2005 / 2006. Häufigkeiten und Trends, Einzellokalisation Harnblase (23.2.2010). Im Internet: www.rki.de Stand: 30.11.2010
2. Bjerregaard B K., Raaschou-Nielsen O, Sorensen M et al. Tobacco smoke and bladder cancer - in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2006 119 2412-2416 (Pubitemid 44546965)
3. Bichler K -H, Harzmann R, (Hrsg). Das Harnblasenkarzinom. Heidelberg Springer 1984
4. Cohen S M., Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol 2000 205 105-115 (Pubitemid 32056470)
5. Nortier J L., Muniz Martinez M -C, Schmeiser H H. et al. Urothelial carcinoma associated with the use of a chinese herb (Aristolochia Fangchi). N Engl J Med 2000 23 1686-1692 (Pubitemid 30354515)
6. Bedemann K -H, Beth-Hübner M, Brock T et al. BK-Report 1 / 2009 Aromatische Amine. Sankt Augustin BGIA 2009
7. Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nature Clin Pract Urol 2007 4 205-217 (Pubitemid 46567153)
8. Svatek R S., Lotan Y. Is there a rationale for bladder cancer screening? Curr Urol Rep 2008 9 339-341
9. Lotan Y, Shariat S F., The NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. Br J Urol Int 2008 101 1362-1367 (Pubitemid 351623980)
10. Lotan Y, Svatek R S., Sagalowsky A. Should we screen for bladder cancer in a high-risk population? Cancer 2006 107 982-990
11. Nasterlack M, Scheuermann B, Messerer P et al. Harnblasenkrebs in einem Risikokollektiv - klinische und epidemiologische Aspekte. Symposium Medical 2001 12 17-19
12. Feil G, Bontrup H, Nasterlack M et al. Prospektive Studie bei Risikopersonen zur Früherkennung von Harnblasenkarzinomen mittels urinbasierter Tumormarker. Der Urologe 2007 46 550-551
13. Pesch B, Feil G, Brüning T et al. Früherkennung von Harnblasenkrebs mit Tumormarkern in einem Kollektiv mit vorheriger beruflicher Exposition gegenüber aromatischen Aminen. Arbeitsmed Sozialmed Umweltmed 2010 45 467-472
14. Jacobs B L., Lee C T., Montie J E. Bladder Cancer in 2010. How Far Have We Come? CA Cancer J Clin 2010 60 244-272
15. Rodgers M, Nixon J, Hempel S et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006 10 iii-iv xi-259
16. Lokeshwar V B., Habuchi T, Grossman H B. et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005 66 35-63 (Pubitemid 43049608)
17. Messing E M., Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990 32 838-845 (Pubitemid 20301387)
18. Fünfstück R, Stein G. Erythrozyten im Urin: Glomerulonephritis oder andere Blutungsquelle? Die Antwort gibt Ihnen Ihr Mikroskop. Fortschr Med 2000 146 30-32 (Pubitemid 30145892)
19. Pesch B, Nasterlack M, Eberle F et al. The role of hematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU International 2011
20. Sullivan P S., Chan J B., Levin M R. et al. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2010 2 412-440
21. Papanicolaou G N., Marshall V F. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945 101 519
22. Bubendorf L, Grilli B, Sauter G et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001 116 79-86
23. Halling K C., King W, Sokolova I A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000 164 1768-1775
24. Glas A S., Roos D, Deutekom M et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003 169 1975-1982 (Pubitemid 36576701)
25. Lotan Y, Elias K, Svatek R S. et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009 182 52-57
26. Kelly A E., Ghenoiu C, Xue J Z. et al. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010 330 235-239
27. Caldas H, Fangusaro J R., Boué D R. et al. Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis. Blood 2007 109 1479-1489 (Pubitemid 46239579)
28. Hanahan D, Weinberg R A. The hallmarks of cancer. Cell 2000 100 57-70 (Pubitemid 30046295)
29. Smith S D., Wheeler M A., Plescia J et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001 285 324-328 (Pubitemid 32095036)
30. Shariat S F., Karakiewicz P I., Godoy G et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study. Clin Cancer Res 2009 15 7012-7019
31. Kinders R, Jones T, Root R et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998 4 2511-2520 (Pubitemid 28477919)
32. Austyn J M., Wood K J. Principles of cellular and molecular immunology. Oxford Oxford University Press 1993 522-554
33. Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008 71 718-722 (Pubitemid 351447297)
34. Raitanen M P., FinnBladder Group. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008 26 45-50
35. Mahnert B, Tauber S, Kriegmair M et al. BTA-TRAK - a useful diagnostic tool in urinary bladder cancer? Anticancer Res 1999 19 2615-2619 (Pubitemid 29392422)
36. Shirodkar S P., Lokeshwar V B. Potential new markers in the early detection of bladder cancer. Curr Opin Urol 2009 19 488-493
37. Schäfer A, Stephan C, Busch J et al. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010 7 286-297
38. Baker S G., Kramer B S., McIntosh M et al. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clinical Trials 2006 3 43-56
39. Habuchi T, Marberger M, Droller M J. et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005 66 64-74 (Pubitemid 43049609)
40. Feil G, Bichler K H., Päulgen-Nelde H J. et al. Urinzytologie beim Harnblasenkarzinom. Diagnostische Wertigkeit eines neuen immunologischen Fluoreszenztestes. Urologe A 2003 42 531-537
41. Rathert P. Urinzytologie beim Harnblasenkarzinom: Kritische Wertung. Urologe A 2003 42 908-911 (Pubitemid 36958566)
42. Stenzl A, Jocham D, Jichlinska P et al. Photodynamische Diagnostik im Harntrakt. Konsensusempfehlungen des Arbeitskreises Onkologie der Deutschen Gesellschaft für Urologie. Urologe A 2008 47 982-987
43. Riley G F., Potosky A L., Lubitz J D. et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995 33 828-841